523 Davis Drive
18 articles with Locus Biosciences
Locus Biosciences Announces First Patient Treated in the ELIMINATE Registrational Phase 2/3 Trial of LBP-EC01 for Urinary Tract InfectionsMarks first randomized Phase 2/3 trial of CRISPR-enhanced bacteriophage precision medicine
Locus Biosciences, Inc. announced that the ELIMINATE trial has begun enrolling patients and the first patient has been treated. ELIMINATE is a registration-enabling Phase 2/3 clinical trial of lead candidate LBP-EC01.
CosmosID® Announces Microbiome Partnership with Locus Biosciences to Provide Long-Term Clinical Trial Support
CosmosID® today announced a partnership for long-term support for Locus' clinical trial initiatives.
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
Locus Biosciences Announces $35 Million Financing
Locus Biosciences, Inc. today announced that it completed a $35 million financing which included a Series B equity financing and conversion of an earlier convertible note.
Locus Biosciences' CRISPR-Cas3-enhanced bacteriophage (crPhage™) product attacks harmful bacteria in the microbiome while sparing human cells.
Locus Biosciences Secures Financing of up to $25 Million from Hercules CapitalProceeds to be used to advance development of synthetic biology engine and manufacturing capabilities
Locus Biosciences, Inc. today announced that the company has entered a credit facility of up to $25 million with Hercules Capital, Inc. (NYSE: HTGC), a specialty financing lender for life science and technology companies.
Locus Biosciences completes first-of-its-kind controlled clinical trial for CRISPR-enhanced bacteriophage therapyPhase 1b trial demonstrates that the company’s lead precision medicine asset is safe and well tolerated
Locus Biosciences, a clinical-stage biotechnology company, announced today the completion of its Phase 1b clinical trial of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage (crPhage™) precision medicine product targeting Escherichia coli (E. coli) bacteria causing urinary tract infections (UTIs).
Locus Biosciences signs contract with CARB-X to advance $14 million precision medicine program to develop crPhage™ product targeting Klebsiella pneumoniae infections
Locus Biosciences announced that it has signed a contract with the global non-profit, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator to fund up to $12.5 million of a $14.8 million program for development of LBP-KP01, a CRISPR Cas3-enhanced bacteriophage product targeting the bacterial pathogen Klebsiella pneumoniae.
Locus Biosciences signs contract with BARDA to advance $144 million precision medicine program to develop LBP-EC01, a crPhage™ product
Locus Biosciences announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target Escherichia coli ( E. coli ) bacteria causing recurrent urinary tract infections
Clinical Catch-Up: January 6-10, 2020
1/13/2020The first full business week of the new year began with plenty of clinical trial news. Here’s a look.
Locus Biosciences initiates world's first controlled clinical trial for a CRISPR enhanced bacteriophage therapy
Locus Biosciences announced today that it has opened for enrollment a Phase 1b clinical trial evaluating LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target Escherichia coli (E. coli) bacteria causing urinary tract infections (UTIs).
Locus Biosciences selected by FierceBiotech as one of its "Fierce 15" Biotech Companies of 2019
Designating it as one of the most promising private biotechnology companies in the industry.
Anchored by Raleigh, Durham and the Research Triangle Park region, BioSpace’s Bio NC Hotbed is one of the faster-growing areas for biopharma in the U.S.
Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics
Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen)
Under the terms of the deal, Janssen is paying Locus $20 million up front. Locus will be eligible for up to a total of $798 million in development and commercial milestones, as well as royalties on any product sales.
Locus Biosciences acquires EpiBiome's high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics
Acquisition significantly accelerates development of new products targeting antibiotic-resistant pathogens and microbiome indications
Locus Biosciences and IDbyDNA Partner to Develop Companion Diagnostic Test for Pseudomonas Aeruginosa Infection
Once LBx-PA01 reaches the market, the test will ensure that the medication will be given to patients with the greatest opportunity to benefit from it, improving patient outcomes and reducing the overall cost of treatment.
Locus Biosciences Closes $19M Series a Led by ARTIS Ventures for CRISPR-Cas3 Antimicrobials
RTIS Ventures led the round, with additional financing from notable institutional investors Tencent Holdings Limited, Abstract Ventures, and the North Carolina Biotechnology Center, among others.